Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study
- 26 Downloads
The purpose of this study was to determine the optimal regimen of neoadjuvant chemotherapy (NAC) for advanced epithelial ovarian, fallopian tube, and peritoneal cancers.
A clinical information survey involving 171 patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer was conducted. These patients underwent NAC followed by interval debulking surgery at the Hyogo Cancer Center (Hyogo, Japan) between January 2006 and December 2015.
The median observation period was 41 (range 4–138) months. Dose-dense paclitaxel and carboplatin (TC) was administered in 101 patients (59%); tri-weekly TC was administered 70 patients (41%). Median progression-free survival was 21 [95% confidence interval (CI) 18–23] months and 15 (95% CI 13–17) months in the dose-dense TC and conventional-TC group [hazard ratio (HR) = 0.69, 95% CI 0.46–0.96; p = 0.02], respectively. The median overall survival was 59 (95% CI 46–72) and 40 (95% CI 32–57) months in the dose-dense TC group and conventional-TC group (HR = 0.72, 95% CI 0.48–1.06; p = 0.09). Multivariate analysis for progression-free survival demonstrated that dose-dense TC represented an independent prognostic factor (HR = 0.70, 95% CI 0.50–0.99; p = 0.04).
Dose-dense TC is a promising regimen of NAC for advanced epithelial ovarian cancer.
KeywordsDose-dense TC Neoadjuvant chemotherapy Ovarian cancer Interval debulking surgery
TS designed the study, analyzed the data, and wrote the initial draft of the manuscript. SN contributed to design of the research, analysis and interpretation of the data, and assisted in the preparation of the manuscript. KS, MK, KY, TJ, HY, MK, TS, KM, TS, and SY have contributed to data collection and interpretation, and critically reviewed the manuscript. All authors approved the final version of the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This study was approved by the Institutional Review Board of the Hyogo Cancer Center (Hyogo, Japan).
- 6.Fagotti A, Ferrandina G, Vizzielli G et al (2016) Phase III randomised clinical trial comparing primary surgery vs. neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome. Eur J Cancer 59:22–33CrossRefGoogle Scholar
- 7.Onda T, Satoh T, Saito T et al (2016) Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. Eur J Cancer 64:22–31CrossRefGoogle Scholar
- 11.Katsumata N, Yasuda M, Isonishi S et al (2013) Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 14:1020–1026CrossRefGoogle Scholar
- 25.Bogani G, Matteucci L, Tamberi S et al (2017) The impact of number of cycles of neoadjuvant chemotherapy on survival of patients undergoing interval debulking surgery for stage IIIC-IV unresectable ovarian cancer results from a multi-institutional study. Int J Gynecol Cancer 27:1856–1862CrossRefGoogle Scholar